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Abstract  
The aim of this study is to examine the Chemical processes focused to reduce viral attack and increasing CD4 
counts, HIV viral load after initiation of combination antiretroviral treatment. However by purchasing and assaying 
of selected top-scoring compounds from the library active anti-HIV agents are created. Subsequent synthesis and 
assaying of S10087 analogs proposed by further computational analysis yielded anti- HIV agents. Thus, with the aid 
of computational tools, it was possible to evolve a false positive into a true active. Antiretroviral treatment–naive, 
chronically HIV-infected persons (n = 1376 and n = 1605 for each of the 2 cohorts) are untreated. During the 
observation period (5 months), at least 1 HIV RNA level and 2 CD4 cell counts may be stable. Approximately 35% 
were nonwhite, and 45% had risk factors. Currently, the data would generally support initiation of HAART in 
patients with CD4 cell counts more than 350 cells/µl. However, from the strong potential for confounding in 
observational studies and the lack of adjustment for lead-time bias in many analyses, it is not possible to rule out 
possible long-term detrimental effects of earlier use of HAART. In chemical process we can use these chemicals 
and it is possible to reduce the critical bond in HIV virus and increase the amount of CD 4 counts.  
 
Introduction 
HIV/AIDS has caused more than 35 million deaths since 1973, and an estimated 64.2 million people are 
currently HIV-positive. Despite the availability of the highly active antiretroviral therapy (HAART), 3 million 
HIV/AIDS-related deaths occurred in 2004. The target for the first three drug classes is HIV-1 reverse 
transcriptase (HIV-RT), which is vital to replication of the HIV-1 virus by converting its single-stranded RNA 
into a double- stranded DNA. HIV-RT is a 1000-residue heterodimer consisting of 66-kDa (p66) and 51-kDa 
(p51) subunits. Participants Antiretroviral treatment–naive, chronically HIV-infected persons (n = 1376 and n = 
1605 for each of the 2 cohorts) untreated during the observation period (5 months) and with at least 1 HIV RNA 
level and 2 CD4 cell counts available.  We consider recent data to support the arguments for and against earlier 
initiation of HAART in patients with CD4 cell counts more than 350 cells/µl. The factors, as yet undefined, 
likely drive CD4 cell losses in HIV infection. These findings have implications for treatment decisions in HIV 
infection and for understanding the pathogenesis of progressive immune deficiency. 
 
Background and scope of review 
The main effect of HAART is to suppress viral replication, allowing the individual's immune system to recover 
and protecting him/her from the development of AIDS and death, treatment should be initiated at an early point 
in the individual's course of disease, prior to a time when CD4 cell loss is such that there is substantial risk of 
clinical progression. On the basis of evidence that clinical progression rates were low while the CD4 cell count 
remained above 200 cells/µl but increased rapidly at lower levels, most early treatment guidelines recommended 
that treatment be delayed until the CD4 cell count had fallen below 200 cells/µl. In addition to their role as 
predictors of the clinical outcomes of HIV infection, CD4 cell count and plasma HIV RNA level are commonly 
used as markers of the success of highly active antiretroviral therapy (HAART). To sup- press viral replication 
so that the VL is below the level of detection with standard assays is thus one of the aims at the start of 
antiretroviral treatment.  HIV-infected patients in most developing countries have limited second and third line 
antiretroviral treatment options. In many countries in Asia, second-line combination antiretroviral treatment 
(cART) is not widely accessible. 
 
Methods and Analysis  
The  data  were  collected:  patient  baseline  data, CD4 and  CD8 count,  HIV VL level, prior  and  new AIDS 
defining  illness (ADI), date  and  cause  of death,  prior  and  current  prescribed HAART, and reason  for 
treatment change. CD4 count was calculated by linear regression with the values at time T, before T, and after T, 
and was expressed as changes of cells per micro liter (µL) per year. The HIV VL was related to the CD4 count 
slope at time T. Preliminary  analyses in eligible TAHOD  patients showed that the mean CD4 count  slope was 
significantly higher  in  the  first  6  months   after  cART  initiation than  in the period  afterwards  (179 vs. 44 
cells/µL per year, p < 0.001). The CD4 slopes were therefore calculated from CD4 counts measured 6 months 
after cART initiation. We did not  include  CD4 count  and HIV VL at baseline for the following three  reasons:  
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first, a large  proportion of patients  did not  have the  tests  at treatment initiation (approximately  25% of 
patients  had no CD4 count  and 45% HIV VL, Table 1); second,  the model aimed to help clinicians in this 
region  to assess the status  of immune system with the  clinical information at hand  (e.g., age, hepatitis  status,  
current CD4 count,  time  since treatment  initiation,  etc) where  the baseline information on CD4 count  and  
HIV VL may not  be readily available; and third,  when we included  baseline CD4 and HIV VL in a sensitivity 
analyses based on the subset  of patients with baseline data available, the results  remained  com- parable  with 
the model  without  the baseline CD4 count and HIV VL. The multivariate  models were built using a forward-
step  approach,  the final model  included  covariates  that  remained  significant  at the  0.20 level. Non- 
significant variables were also presented and adjusted for in the final multivariate models. Finally, sensitivity 
analysis was also performed by restricting the records in patients contributing at least 4 or more concurrent CD4 
and HIV VL tests. The intermolecular structural similarity can be measured through distance and association 
coefficients. Association coefficients are used with real-value descriptors or binary data, and are often 
normalized to lie within the range of zero (no similarity at all) and unity (identical sets of descriptors). The 
crystal structures for HIV-RT complexes with the inhibitor UC-781 (PDB ID: 1rt4) and the K103N variant 
complexes with the inhibitor TMC-125 (PDB ID: 1sv5). The top ranked compounds obtained in this way were 
redocked and rescored using the Glide extra-precision (XP) mode. Plasma HIV-2 RNA levels were measured 
using either the Amplicor HIV-1 Monitor assay or the branched DNA assay, and all values were standardized to 
their branched DNA equivalents.   The CD4 cell counts were measured by flow cytometry using standardized 
methods; specific instruments varied according to the institution. Descriptive and other basic statistics were 
computed using Intercooled Stata, version 8.0 (Stata Corp, College Station, Tex). To assess the association 
between plasma HIV RNA concentration and CD4 cell change, we used random-effects linear models (PROC 
MIXED, SAS software v.8.2; SAS Institute Inc, Cary, NC) assuming an un- structured  correlation structure. We 
used log10-transformed values of plasma HIV RNA in all analyses.  To determine the extent to which inter 
individual variability in CD4 cell change was explained by presenting HIV RNA measurement, a single value at 
explaining inter individual variability in CD4 T-cell change, we used a similar approach to generate model-based 
estimates of HIV RNA change per individual  and regressed these estimates on model- derived individual rates 
of CD4 cell loss. Besides the protein energies, the energy-minimized structures for the complexes provided the 
intra molecular and salvation energies for the ligands in the protein environment. In the bound state, it was 
assumed that there is only one conformation accessible to each ligand; its conformational entropy is therefore 
zero. This approximation should be revisited, though it may require a conformational search in the bound state.  
   
The current evidence for and against earlier initiation of HAART and Modifications of   S10087 
The main argument for delaying HAART related to the toxicities and inconvenience of these drugs and the fact 
that treatment was likely to be life-long. It was felt that patients would be unable to maintain the high levels of 
adherence that are required for successful outcomes. Given the perceived low risk of AIDS and mortality at CD4 
cell counts more than 350 cells/µl, it was thought that little would be gained by exposing patients to 
antiretroviral therapy too soon. There is limited evidence to support an increased frequency of toxicities in those 
starting HAART with higher CD4 cell counts. The risk of non-Hodgkin's lymphoma was more than twice as 
high (adjusted hazard ratio of 2.28) in non-HAART users with CD4 cell counts of 200-349 cells/µl compared to 
those with counts ≥350 cells/µl. The risk of serious non-AIDS diseases was also significantly lower in the 
immediate arm. Which differ by replacement of the 4-methyl group with 3-fluoro (S10076), 3-chloro, 4-methyl 
(S10085), and 2, 4-dichloro (S10089). After purification, they were submitted to an anti-HIV assay using 
infected human T-cells, but they failed to inhibit HIV replication in the MT-2 cells at concentrations up to 100 
µM. 
 
Chemical Similarity Search and Process 
These four different solutions that minimize the HIV complex bond viral factors simultaneously were obtained, 
specifically 62% and 54% for the Euclidean and Tanimoto coefficients, respectively. In each solution, the 
Euclidean and Tanimoto coefficients have identical sets of descriptors, whereas the descriptors for the first are 
weighted.  We used two chemicals for the HIV-I reverse transcriptase process. They are oxalamide linker and 
tetra methyl piperidine. In oxidation process can use H2N; but it is a triple bond highly react able chemical. In 
this chemical progress (CONH2)2 gets oxidized from hydrogen cyanide to cyanogens. These chemicals cause 
reaction with body fluids in a fraction of second and also it will block the hydrogen molecules in our body cells. 
Hence we use is called oxalamide linker and due to which single bond NH and double bond oxide is formed. For 
the HIV-2 reverse transcriptase process; we are adding P- substituted phenyl ring with these two chemicals.  
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Fig.1. Chemical similarity process in reactive bond higher order chemical reaction 
As a link Br is added to P substituted phenyl ring. P denoted Para. It is used for purpose of producing cl. 
Why we do not go for Meta and ortho is that it produces nitric. Phenyl is a normal chemical. Phenyl ring has a 
high bond and hence, it cannot be destructed. When HIV virus attacks phenyl ring; chlorine gets produced. The 
molecules in the chemicals are arranged in the form of chair confirmation.  According to genetics and the pattern 
used for chair confirmation is T257, G473, S375, E370, G429, N425, and W427. These chair confirmation keeps 
on changing. Phenyl is produced from benzene (C6H5). Phenyl groups tend to resist oxidation and reduction. It is 
used to lower cholesterol in people with hyper cholestrolaemia. Considering normal chemical reaction as base; if 
weak nudeophile and moderate electrophile are added; no reaction occurs. Considering the previous reaction; 
weak nudeophile is replaced by bromo benzene and p substituted phenyl ring is added. Similarly moderate 
electrophile is replaced by oxalamide linker and tetra methyl piperidine. During the chemical similarity process 
Para isomers substitute bromo benzene phenyl ring reacts with HIV virus and hence chlorination occurs for 55-
65%. So this chemical process acts as an antibiotic and it will reduce the critical bonding of HIV chemical bond. 
After that we will calculate CD4 counts. MW (molecular weight), FOSA (the hydrophobic component of the 
total solvent accessible surface area (SASA)), FISA (the hydrophilic component of SASA), and HB donor 
(number of hydrogen bonds donated by the solute to water molecules), appear in all solutions. The amino group 
in 23p and 23o is responsible for the larger de salvation and intra molecular penalties, but provides a more 
favorable electrostatic interaction with the enzyme due to hydrogen bonding with the Glu138 carboxyl ate group.  
The pyrimidine and the diarylamino nitrogens are now hydrogen bonded to the backbone nitrogen and oxygen 
atoms of Lys102, while the amino group of TMC-125 is no longer hydrogen bonded to Glu138. In spite of that, 
the activity of TMC-125 is not significantly affected by the K103N mutation.  
 
Fig.2. Energy-minimized complexes structure for chemical similarity process. 
Process of CD4 counts and treatment response of different CD4 levels  
In particular, reported that only 20, 26, and 46% of those starting HAART with CD4 cell counts of less than 50, 
50-200, and 200-350 cells/µl reached a CD4 cell count more than 800 cells/µl after 7 years of uninterrupted 
HAART compared to 73 and 87% of those starting HAART with CD4 cell counts of 350-500 and ≥500 cells/µl. 
It is important to consider that there may be a CD4 cell count 'ceiling' above which an individual's CD4 cell 
count is unlikely to rise - this may result in an inverse association between the pre-HAART CD4 cell count and 
CD4 increases. Thus, immune activation may be a major determinant of T-cell turn- over and CD4 cell depletion 
in chronic HIV infection both in human and animal hosts. Our results provide further support for additional 
studies exploring the relative contribution of immune activation to the pathogenesis of immune deterioration in 
treatment- naive, HIV-infected persons. Recently, investigators from the North American AIDS Cohort 
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Collaboration on  Research and Design (NA-ACCORD) group reported that initiation of HAART at a CD4 cell 
count between 350 and 500 cells/µl was associated with a 70% improvement in survival compared to starting 
HAART at lower CD4 cell counts; the authors also used methods to take account of lead-time bias. The below 
slope was associated with age (-5.7 cells/µL per year per 10-year age increase, p = 0.013), concurrent HIV VL (-
42.1 per 1 log10 copies/mL  VL increase,  p < 0.001), concurrent CD4 count  (+1.9 per 100 cells/µL increase), 
disease stage (compared  to CDC category  A illnesses: +29.2 if diagnosed with tuberculosis  [TB] with or 
without other  ADI, p < 0.001; +15.7 if diagnosed  with non-TB ADI, p = 0.011), hepatitis  B or C co-infection  
(-21.3 if co- infected,  p = 0.007), and  time  since cART initiation (compared  to CD4 slope during  6-12 months:  
-23.8 during 12-18 months,  p = 0.130; -39.5 during  18-24 months, p = 0.005; -64.8 at 24 months  or later, p < 
0.001). The CD4 counts continues to increase with HIV VL up to 5 000 copies/mL   during 12-18 months   after 
cART. If this patient was hepatitis co-infected, the CD4 count starts to fall when the HIV VL increases up  to 3 
000 copies/mL . 
Table.1. Analyses of CD4 count (slope, cells/µL per  year) 
  
Difference*
Univariate 
(95% CI) 
 
p value 
 
Difference*
Multivariate** (95% CI) 
p value
Sex        
 Male* 0.0   0.0   
 Female 8.6 (0.1, 16.7) 0.039 8.9 (-1.7, 15.1) 0.097 
Current  age         
 per 10 years older -7.3 (-16.2, -3.1) 0.001 -5.7 (-14.4, -2.0) 0.013 
Disease  stage         
 CDC Category A* 0.0   0.0   
TB with or without other ADI27.5 (17.2, 38.3) < 0.001 29.2 (15.6, 39.9) < 0.001 
 Non-TB  ADI(s) 5.3 (-7.2, 15.3) 0.423 15.7 (3.5, 23.2) 0.011 
Hemoglobin  level         
per 1 g/dL higher 0.0 (-0.0, 0.1) 0.661 0.0 (-0.0, 0.1) 0.689 
Concurrent  CD4  count  
Per 100 cells/µL higher 2.1 (-0.4, 4.0) 0.321 2.9 (0.2, 4.7) 0.224 
Concurrent  viral  load       
per log10 copies/mL higher -42.3 (-51.8, -37.5)< 0.001 -42.1 (-51.3, -36.7) < 0.001 
Hepatitis  B  or  C  co infection  
No* 0   0   
Yes -23.7 (-37.3, -7.6) 0.005 -21.3 (-34.9, -5.1) 0.007 
Time  since  cART  initiation  
> 6 to ≤ 12 months* 0.0   0.0   
> 12 to ≤ 18 months -23.6 (-39.7, -5.3) 0.131 -23.8 (-39.8, -5.5) 0.130 
> 18 to ≤ 24 months -37.1 (-43.1, -7.4) 0.007 -39.5 (-46.2, -9.5) 0.005 
> 24 or more months -63.7 (-82.4, -53.1)< 0.001 -64.8 (-83.5, -54.2) < 0.001 
Initial  cART  containing  NNRTI  
No* 0.0   0.0   
Yes 7.1 (-1.4, 17.3) 0.235 -2.5 (-9.2, 8.9) 0.874 
Initial  cART  containing  boosted  PI  
No* 0.0   0.0   
Yes -1.1 (-13.7, 6.0) 0.893 -4.5 (-16.1, 3.3) 0.440 
Initial  cART  containing  abacavir  
No* 0.0      
Yes -13.7 (-26.3, 0.0) 0.078 -7.6 (-19.7, 7.3) 0.072 
  
Results and discussion  
1378 to 1605 naïve patients initiated cART, and had three or more concurrent CD4 and HIV VL data pairs 
available beyond 6 months after cART initiation. After cART initiation, viral logical suppression (HIV VL < 400 
copies/ mL) was achieved in 83% of patients at 6 month and 82% in 12 months. Table   shows the random-effect 
linear regression analysis of the CD4 count slope. Concurrent hemoglobin level, initial cART containing NNRTI 
or boosted PI were not significantly associated with the study endpoint in both Univariate and multivariate 
analyses. Recommendations for earlier treatment are therefore unlikely to have any major effect on population-
level outcomes, and it is argued that the resources required for earlier treatment may be better used to encourage 
earlier HIV testing in these countries, or enabling full access to HAART in countries where drugs are less readily 
available. Jerwin prabu et al observed  in HIV-infected  patients  with  HBV or  HCV an initially delayed CD4 
count  recovery at week four after HAART treatment, but  at week 48 the  CD4 count  increase  was similar  to  
the  patients  only infected  with  HIV .  A decrease in CD4 count slope of less than 20 cells might not be 
clinically significant in the early phase of cART. Phenyl groups tend to resist oxidation and reduction. It is used 
to lower cholesterol in people with hyper cholestrolaemia. Considering normal chemical reaction as base; if 
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weak nudeophile and moderate electrophile are added; no reaction occurs. Considering the previous reaction; 
weak nudeophile is replaced by bromo benzene and p substituted phenyl ring is added. Similarly moderate 
electrophile is replaced by oxalamide linker and tetra methyl piperidine. During the chemical similarity process 
Para isomers substitute bromo benzene phenyl ring reacts with HIV virus.  
 
 
Fig.3. Molecular reaction with strong chair confirmation 
 
If CD4 count  is the only way for monitoring treatment  response,  the result  of this analysis showed  
that  a patient  can have a considerable  duration of virological failure without  meeting  CD4 criteria  
recommended by WHO  for switch of ART to second  line, through  the  possible  development of HIV- drug  
resistance  that  could  compromise the  efficacy of later cART regimens  remains  uncertain. 
 
Conclusion 
Subsequent synthesis and assaying revealed that S10087 was in fact a “near-miss” since several closely related 
analogs were found to be potent anti-HIV agents.  A chemical similarity of the HIV-2 reverse transcriptase as 
reference structures in order to identify potentially active compounds.  The results of our study challenge the 
concept that CD4 cell depletion in chronic HIV infection is mostly attributable to the direct effects of HIV 
replication. Thus, with the aid of computational tools, it was possible to evolve a false positive from the virtual 
screening into a true active.  In this research we have summarized the evidence for and against earlier initiation 
of HAART in HIV- infected individuals with a CD4 cell count more than 350 cells/µl. The effect on long-term 
outcomes through the possible development of HIV drug resistance remains uncertain.  
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